We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+67.05%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$486M
AUM Growth
+$109M
Cap. Flow
+$86.4M
Cap. Flow %
17.77%
Top 10 Hldgs %
56.66%
Holding
71
New
17
Increased
8
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$61.6M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$15.3M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$12.9M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$8.22M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.49M

Top Sells

Rank Stock Value
1
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.5M
2
CELG
Celgene Corp
CELG
+$17.2M
3
OMER icon
Omeros
OMER
+$8.05M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$7.2M
5
MRK icon
Merck
MRK
+$5.79M

Sector Composition

Rank Sector Weight
1 Healthcare 79.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZSPH
51
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$1.96M 0.4%
+50,000
New +$1.65M
ALDR
52
DELISTED
Alder Biopharmaceuticals
ALDR
$1.9M 0.39%
150,000
– –
DARE icon
53
Dare Bioscience
DARE
$19.2M
$1.9M 0.39%
3,750
– –
AKTX
54
Akari Therapeutics
AKTX
$12.9M
$1.49M 0.31%
31
+18
+138% +$839K
RGLS
55
DELISTED
Regulus Therapeutics
RGLS
$1.37M 0.28%
1,667
– –
CLRB icon
56
Cellectar Biosciences
CLRB
$21.3M
$1.18M 0.24%
+18
New +$1.55M
ADXS
57
DELISTED
Advaxis Inc
ADXS
$1.18M 0.24%
+23,333
New +$1.11M
AGTC
58
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.13M 0.23%
60,600
-158,000
-72% -$2.86M
AGRX
59
DELISTED
Agile Therapeutics
AGRX
$1.09M 0.23%
75
– –
NERV icon
60
Minerva Neurosciences
NERV
$185M
$1.06M 0.22%
+21,875
New +$1.16M
BMY icon
61
CALL
Bristol-Myers Squibb
BMY
$134B
$985K 0.2%
+5,000
New +$250K
CRIS icon
62
Curis
CRIS
$10M
$846K 0.17%
300
– –
SCYX icon
63
SCYNEXIS
SCYX
$50.3M
$739K 0.15%
1,250
– –
SAGE
64
DELISTED
Sage Therapeutics
SAGE
$315K 0.06%
+10,000
New +$290K
ACAD icon
65
Acadia Pharmaceuticals
ACAD
$4.39B
– –
-50,000
Closed -$1.13M
MRK icon
66
Merck
MRK
$316B
– –
-104,800
Closed -$5.79M
PBYI icon
67
CALL
Puma Biotechnology
PBYI
$391M
– –
-5,000
Closed -$4.5M
MNK
68
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-90,000
Closed -$7.2M
QCOR
69
DELISTED
QUESTCOR PHARMA INC
QCOR
– –
-200,000
Closed -$18.5M
CELG
70
DELISTED
Celgene Corp
CELG
– –
-200,000
Closed -$17.2M
1 2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cormorant Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Cormorant Asset Management held 71 positions worth $486M, up 29% from $377M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Cormorant Asset Management deployed $86.4M of net new capital in Q3 2014, opening 17 new positions and adding to 8 existing holdings. Its largest new stake was Keryx Biopharmaceuticals Inc: 1,000,000 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier.

On the sell side, the largest reduction was Omeros, an estimated $8.05M trimmed.

  • Cormorant Asset Management's largest Q3 2014 buy was Keryx Biopharmaceuticals Inc: 1,000,000 shares worth $13.8M.
  • Cormorant Asset Management added most to Puma Biotechnology in Q3 2014, an estimated $61.6M increase.
  • Cormorant Asset Management's biggest Q3 2014 reduction was Omeros, cutting an estimated $8.05M.
  • Cormorant Asset Management fully exited QUESTCOR PHARMA INC in Q3 2014, selling an estimated $18.5M.
  • Cormorant Asset Management's ten largest holdings make up 57% of its $486M portfolio in Q3 2014.
  • Cormorant Asset Management opened 17 new positions and closed 6 in Q3 2014.
  • Cormorant Asset Management's portfolio value rose 29% quarter-over-quarter to $486M.

Based on Cormorant Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.